Aurobindo Pharma has closed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries. The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on July 14, 2018.
Jefferies International acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
